Study: Boston Sci's drug-eluting stent safe, despite FDA warning

Boston Scientific ($BSX) is touting a study that says its Promus stent, which administers the immunosuppressant everolimus, is safe for use, with "excellent" results over a two-year period. The drug-eluting stent was approved by the FDA last year, but the agency required Boston Sci to warn physicians that, in some cases, the stent's struts can become deformed over time, which can lead to clotting or heart attack. However, no such cases were reported in the company's study. Report

Suggested Articles

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a…

Counting on a novel nasal-spray device to set it apart from its rivals, drug delivery specialist OptiNose is preparing to file its new chronic rhinosinusitis…